Amgen Inc.

Equities

AMGN

US0311621009

Real-time Estimate Cboe BZX Other stock markets 12:16:31 2026-04-10 pm EDT			5-day change	1st Jan Change
352.43 ^USD	-0.89%		+2.93%	+7.73%

10:29am	BeOne Medicines Says Tarlatamab Received Marketing Authorization in China for Small Cell Lung Cancer Treatment	MT
08:44am	Wall Street Gets a CPI Lifeline

Transcript : Amgen Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-11-2026 09

Published on 03/11/2026 at 10:20 am EDT - Modified on 03/11/2026 at 12:21 pm EDT

S&P Capital IQ

Presenter Speech
David Risinger (Analysts)

We're ready to get started. On behalf of Leerink Partners, I wanted to welcome you all to the session with Amgen. So very much my pleasure to welcome Peter

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Amgen Inc.

10:29am	BeOne Medicines Says Tarlatamab Received Marketing Authorization in China for Small Cell Lung Cancer Treatment	MT
08:44am	Wall Street Gets a CPI Lifeline
04:10am	Amgen's lung cancer drug tarlatamab wins China approval	RE
Apr. 09	Guggenheim Adjusts Amgen Price Target to $351 From $347, Maintains Neutral Rating	MT
Apr. 07	Amgen Inc CEO Robert A. Bradway 2025 total compensation $24.7 million	RE
Apr. 07	Viridian Therapeutics' Thyroid Eye Disease Franchise Maintains $1 Billion Opportunity, RBC Says	MT
Apr. 07	RBC Capital Adjusts Amgen Price Target to $370 From $360, Maintains Outperform Rating	MT
Apr. 06	Health Care Down on Earnings Doubts -- Health Care Roundup	DJ
Apr. 06	Viridian Shares Fall After Competing Amgen Eye Drug Performs Well	DJ
Apr. 06	Top Midday Stories: Iran Reportedly Rejects Proposed Ceasefire; Soleno Shares Rise After $2.9 Billion Neurocrine Deal	MT
Apr. 06	Amgen Says Phase 3 Trial of Subcutaneous Tepezza in Thyroid Eye Disease Meets Endpoints	MT
Apr. 06	Amgen Posts Strong Phase 3 Trial Data for Subcutaneous Tepezza	DJ
Apr. 06	Amgen reports positive topline phase 3 results for subcutaneous tepezza in thyroid eye disease	RE
Apr. 06	Amgen Announces Positive Topline Phase 3 Results for Subcutaneous TEPEZZA in Adults Living with Moderate-To-Severe Active Thyroid Eye Disease	CI
Apr. 02	Global pharma companies that have publicly announced Trump drug pricing agreements	RE